The Food Safety and Standards Authority of India (FSSAI) has taken a proactive measure to tackle the issue of spurious drugs manufactured by nutraceutical companies across the country.
A press release on this initiative was issued on 20th June 2023.
Authority had started this surveillance drive from Himachal Pradesh.
As part of this drive, 21 facilities operating in Baddi, Himachal Pradesh were inspected and 111 samples have been lifted from 7th to 9th June 2023.
FSSAI has planned to inspect 25-30 percent of the nutraceutical manufacturing facilities in Himachal Pradesh by the end of June 2023.
The aim is to identify and take immediate action against defaulting FBOs to ensure consumer safety and the integrity of the nutraceutical industry.
FSSAI CEO proactively held a meeting with the major manufacturers of health supplements and nutraceuticals of Baddi, Himachal Pradesh on Tuesday, June 20th, 2023 at FSSAI headquarters to address the issue.
During the meeting, the CEO, of FSSAI issued a stern warning, emphasizing the absolute necessity for strict compliance with nutraceutical regulations.
Non-compliance was highlighted as having severe consequences, including the possibility of license suspension or cancellation, as well as the initiation of criminal cases.
Recognizing the significance of a coordinated effort, the FSSAI has directed the Commissioner of Food Safety, Himachal Pradesh, to provide full support in carrying out the surveillance drive effectively.
What is the penalty for FBOs in case of spurious drug manufacturing?
FBOs found to be in violation may be prosecuted under Section 59 of the FSS Act 2006 where punishment like life imprisonment or a fine of not less than Rs. 10 lakhs will be imposed.
Which FSSAI app is meant for consumer grievances related to food safety?
To facilitate the involvement of citizens in maintaining food safety, FSSAI also provides a dedicated consumer grievance portal, the Food Safety Connect app, available on both iOS and Android platforms.
Through this user-friendly platform, individuals can promptly report any non-compliance or violations they come across, enabling the FSSAI to take swift action and address the issues effectively.
Conclusion
FBOs must avoid manufacturing any non-standardized products in Nutraceutical manufacturing plants that can fall under the drug definition and adhere to the set guidelines of FSSAI for the manufacturing and sale of health supplements and nutraceutical products.
